Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Heading for startup Denali, Tessier-Lavigne to leave Pfizer board |
||||||||||||||||||||
Shortly after the news broke of the formation of Denali Therapeutics, Pfizer ($PFE) director Marc Tessier-Lavigne announced that he would step down from the pharma's board to serve as chairman at Denali. Aimed at tackling neurodegenerative diseases, Denali announced a $217 million Series A round this week and support from an impressive roster of high-profile biopharma personnel. Tessier-Lavigne was appointed to Pfizer's board in December 2011 and most recently served as a member of the Regulatory and Compliance Committee as well as the Science and Technology Committee. "While we regret the loss of Marc's service, we congratulate him on the launch of Denali and offer him our best wishes for all of his future endeavors," said Ian Read, Pfizer chairman and CEO. Story | Release
|